Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

临床核心：IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性

基本信息

批准号：
10589805
负责人：
MICHAEL E PICHICHERO
金额：
$ 30.47万
依托单位：
BOSTON CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-03-10 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10589805
关键词：
3 year old Adjuvant Africa Age Antibody Response Asthma Canada Child Child Health Clinical Clinical Trials Communicable Diseases Data Development Disease Functional disorder Future Geography Goals Growth Health Hypersensitivity Immune Immune System Diseases Immune response Immune system Immunologic Memory Immunologics Immunology procedure Impairment Incidence Infant Infection Infection prevention Intervention Intestines Investigation Lead Life Longitudinal cohort study Measures Modernization Molecular Mucous Membrane Nasopharynx Papua New Guinea Phenotype Population Predisposition Prospective cohort Proteins Proteomics Respiratory Tract Infections Sampling Secure Shapes Systems Biology Testing Vaccination Vaccines Validation Variant biobank biomarker development biomarker discovery clinical phenotype cohort data exchange early childhood immune modulating agents metabolomics microbiome research mortality multiple omics predictive marker prevent prospective recruit respiratory tool transcriptomics vaccine response vaccine-induced antibodies

项目摘要

Project Summary/Abstract – Clinical Core (CC) The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection- specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically, the CC will: 1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART, Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to Cores/Projects for OMIC and immune assays; 2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and 3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins, metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future investigations.

项目总结/摘要 – 临床核心 (CC) 临床核心（CC）将提供并协调现有生物样本库和新的前瞻性临床样本的共享从过去和现在的全身和粘膜（肠和鼻咽）室收集的样本正在进行的早期儿童队列研究，以表征疫苗反应特异性、呼吸道感染的特征这些发现将为干预措施提供信息。可能会将与疾病相关的不利理想内型重定向到与健康相关的内型。中央委员会将： 1. 协调来自四个早期生命队列（EPIC-HIPC、VDAART、罗切斯特联合队列（RCC）和儿童）将共同组成我们的理想元队列（IMC） OMIC 和免疫分析的核心/项目； 2. 测量 VDART 和 CHILD 队列中疫苗诱导的抗体水平；以及 3. 招募一个明确的前瞻性婴儿队列，为验证测试提供新样本，确认预测生物标志物、测试机制假设、识别免疫调节剂（例如蛋白质、代谢物、佐剂或疫苗）克服受损的表型，并为未来确保新的生物储存库调查。